Skip to main content
News

Boosted by $3 million in seed funding, Queen Mary spin-out heralds developments in cancer immunotherapies and a vision of immune system stimulation

VacV Biotherapeutics (VacV), a cancer immunotherapy company and Queen Mary spin-out developing innovative viral-based therapies, has advanced its promising pipeline of pre-clinical treatments after strong testing results thus far.

Published on:

For media information, contact:

Press Office
email: press@qmul.ac.uk
Back to top